Indiana University Research and Technology Corp., which advances intellectual property developed at IU so it can be commercialized by industry, has optioned technology to Allinaire Therapeutics that could treat patients affected by lung-related diseases. Allinaire Therapeutics was launched by BioMotiv, a Cleveland-based drug-development accelerator.
“They have demonstrated that a therapeutic antibody against this target has a strong potential to slow the progression of the disease,” Shah said. “We look forward to working with them to advance their discoveries into breakthrough medicines to help patients with COPD and other pulmonary diseases.”
For more information, click here.